Abstract: This disclosure provides systems and methods for patient-specific identification and assessment of ocular disease risk factors and efficacy of various treatments. The systems and methods can include mathematically modeling an expected normal patient-specific value of one or more clinically observable properties using a patient-specific mathematical model that can be calibrated with patient-specific data. The expected normal patient-specific value can be compared with a measured patient-specific value. A greater difference between the expected and measured patient-specific values can correlate to greater ocular vasculature abnormalities.

Abstract: A composition for lowering blood pressure comprising an effective amount of a carotenoid selected from among a group consisting of lycopene, phytofluene, phytoene, astaxanthin and cathaxanthin or mixtures thereof. Further disclosed is a method for lowering blood pressure.

Abstract: There is disclosed a method for treating and/or preventing macular edema and age-related macular degeneration which comprises topical administration of carbonic anhydrase inhibitors to the eye.

Abstract: There is disclosed a method for increasing retinal and optic nerve head blood velocity by topical application of carbonic anhydrase inhibitors to the eye.